Moberg Pharma and Colep, a global player in the consumer goods packaging and contract manufacturing industries, entered a development agreement for MOB-015—a novel topical formulation of terbinafine for onychomycosis (nail fungus). Colep’s healthcare division will share funding by conducting a pharmaceutical development program which will include scale-up of manufacturing processes, stability programs and supply of clinical trial material for the phase 3 program for MOB-015 as well as the doc...